{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:21:49Z","timestamp":1781047309116,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>No standard treatment is available for advanced biliary tract cancer (BTC) after first-line therapy with gemcitabine plus cisplatin (GEMCIS). The objective of this study was to evaluate safety and anti-tumour activity of fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX) as salvage treatment in patients with previously treated advanced BTC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this two-stage phase 2 study, patients with advanced BTC who had disease progression or unacceptable toxicity after \u22653 cycles of GEMCIS were eligible. Primary endpoints were safety and efficacy (defined as objective response rate, ORR). In stage one, ten patients were treated with FOLFIRINOX every 2 weeks. In stage two, an additional 20 patients were enrolled at a starting dose as defined in stage one, provided that in stage\u2009\u22651 objective response or\u2009\u22652 stable diseases were observed and\u2009\u22643 patients had serious adverse events (SAEs) within the first 6 weeks of treatment. Secondary endpoints were progression-free survival (PFS) and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty patients were screened for eligibility and 30 patients were enrolled. In stage one, one patient had a partial response and five patients had stable disease. One patient had a SAE during the first 6 weeks of treatment, and five patients required a dose reduction due to adverse events. The most common grade 3\u20134 adverse events in stage one were neutropaenia, mucositis and diarrhoea. Stage two was initiated with FOLFIRINOX in an adapted dose. In stage two, grade 3\u20134 neutropaenia, diarrhoea, nausea and vomiting were the most common adverse events. The ORR, median PFS and OS in all patients were 10%, 6.2 and 10.7 months, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In patients with advanced BTC who progressed after or were intolerant to GEMCIS, FOLFIRINOX can be administered safely and could be considered as an option for salvage treatment in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier NCT02456714.<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41416-019-0698-9","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:04:46Z","timestamp":1578614686000},"page":"634-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial"],"prefix":"10.1038","volume":"122","author":[{"given":"Ali","family":"Belkouz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-1766","authenticated-orcid":false,"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A. A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry A. L. M.","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"van Gulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn G. H.","family":"van Oijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J. A.","family":"Punt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"698_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2017.1747","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 3, 524\u2013548 (2017).","journal-title":"JAMA Oncol."},{"key":"698_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius, B., Hoffman, K., Sjoden, P. O., Jacobsson, G., Sellstrom, H., Enander, L. K. et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 7, 593\u2013600 (1996).","journal-title":"Ann. Oncol."},{"key":"698_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."},{"key":"698_CR4","doi-asserted-by":"crossref","unstructured":"Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A. et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin \/ 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy. J. Clin. Oncol. 37 (Suppl. 15), 4003 (2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.4003"},{"key":"698_CR5","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1002\/cncr.29471","volume":"121","author":"B Brieau","year":"2015","unstructured":"Brieau, B., Dahan, L., De Rycke, Y., Boussaha, T., Vasseur, P., Tougeron, D. et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Ent\u00e9rologues Oncologues. Cancer 121, 3290\u20133297 (2015).","journal-title":"Cancer"},{"key":"698_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/bjc.2016.446","volume":"116","author":"BJ Kim","year":"2017","unstructured":"Kim, B. J., Yoo, C., Kim, K. P., Hyung, J., Park, S. J., Ryoo, B. Y. et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br. J. Cancer 116, 561\u2013567 (2017).","journal-title":"Br. J. Cancer"},{"key":"698_CR7","doi-asserted-by":"crossref","unstructured":"Lamarca, A., Hubner, R. A., David Ryder, W. & Valle, J. W. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann. Oncol. 25, 2328\u20132338 (2014).","DOI":"10.1093\/annonc\/mdu162"},{"key":"698_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000226214","volume":"77","author":"T Sasaki","year":"2009","unstructured":"Sasaki, T., Isayama, H., Yashima, Y., Yagioka, H., Kogure, H., Arizumi, T. et al. S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 77, 71\u201374 (2009).","journal-title":"Oncology"},{"key":"698_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s10637-010-9553-9","volume":"30","author":"T Sasaki","year":"2012","unstructured":"Sasaki, T., Isayama, H., Nakai, Y., Mizuno, S., Yamamoto, K., Yagioka, H. et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Investig. New Drugs 30, 708\u2013713 (2012).","journal-title":"Investig. New Drugs"},{"key":"698_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00280-013-2106-0","volume":"71","author":"E Suzuki","year":"2013","unstructured":"Suzuki, E., Ikeda, M., Okusaka, T., Nakamori, S., Ohkawa, S., Nagakawa, T. et al. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother. Pharmacol. 71, 1141\u20131146 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"698_CR11","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1080\/0284186X.2016.1191670","volume":"55","author":"S Sebbagh","year":"2016","unstructured":"Sebbagh, S., Roux, J., Dreyer, C., Neuzillet, C., de Gramont, A., Orbegoso, C. et al. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. Acta Oncol. 55, 1168\u20131174 (2016).","journal-title":"Acta Oncol."},{"key":"698_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/jjco\/hyv148","volume":"46","author":"C Dodagoudar","year":"2016","unstructured":"Dodagoudar, C., Doval, D. C., Mahanta, A., Goel, V., Upadhyay, A., Goyal, P. et al. FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients. Jpn. J. Clin. Oncol. 46, 57\u201362 (2016).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"698_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00280-015-2691-1","volume":"75","author":"IG Hwang","year":"2015","unstructured":"Hwang, I. G., Jang, J. S., Oh, S. Y., Rho, M. H., Lee, S., Park, Y. S. et al. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable\/metastatic biliary tract cancer. Cancer Chemother. Pharmacol. 75, 757\u2013762 (2015).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"698_CR14","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/cncr.31938","volume":"125","author":"MR Sharma","year":"2019","unstructured":"Sharma, M. R., Joshi, S. S., Karrison, T. G., Allen, K., Suh, G., Marsh, R. et al. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer 125, 1629\u20131636 (2019).","journal-title":"Cancer"},{"key":"698_CR15","doi-asserted-by":"crossref","unstructured":"Kim, B. M. & Armenio, V. A. Efficacy and safety of FOLFIRINOX in advanced cholangiocarcinoma. J. Clin. Oncol. 35 (Suppl. 15), e15620 (2017).","DOI":"10.1200\/JCO.2017.35.15_suppl.e15620"},{"key":"698_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12029-016-9880-y","volume":"48","author":"T Kus","year":"2017","unstructured":"Kus, T., Aktas, G., Kalender, M. E., Sevinc, A. & Camci, C. Comparison of FOLFIRINOX chemotherapy with other regimens in patients with biliary tract cancers: a retrospective study. J. Gastrointest. Cancer 48, 170\u2013175 (2017).","journal-title":"J. Gastrointest. Cancer"},{"key":"698_CR17","doi-asserted-by":"publisher","first-page":"viii205","DOI":"10.1093\/annonc\/mdy282.144","volume":"29","author":"A Ulusakarya","year":"2018","unstructured":"Ulusakarya, A., Karray, W., Abdou, J., Karabou\u00e9, A., Haydar, M., Krimi, S. et al. FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC). Ann. Oncol. 29, viii205\u2013viii270 (2018).","journal-title":"Ann. Oncol."},{"key":"698_CR18","doi-asserted-by":"crossref","unstructured":"Rauthan, A. & Patil, P. Modified FOLFIRINOX regimen in advanced biliary tract adenocarcinoma. J. Clin. Oncol. 35 (Suppl. 4), 484 (2017).","DOI":"10.1200\/JCO.2017.35.4_suppl.484"},{"key":"698_CR19","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"698_CR20","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.2307\/2533268","volume":"51","author":"J Bryant","year":"1995","unstructured":"Bryant, J. & Day, R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51, 1372\u20131383 (1995).","journal-title":"Biometrics"},{"key":"698_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/COC.0b013e31818c08ff","volume":"32","author":"S Lee","year":"2009","unstructured":"Lee, S., Oh, S. Y., Kim, B. G., Kwon, H. C., Kim, S. H., Rho, M. H. et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am. J. Clin. Oncol. 32, 348\u2013352 (2009).","journal-title":"Am. J. Clin. Oncol."},{"key":"698_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000479970","volume":"94","author":"FO Larsen","year":"2018","unstructured":"Larsen, F. O., Markussen, A., Diness, L. V. & Nielsen, D. Efficacy and safety of capecitabine, irinotecan, gemcitabine, and bevacizumab as second-line treatment in advanced biliary tract cancer: a phase II study. Oncology 94, 19\u201324 (2018).","journal-title":"Oncology"},{"key":"698_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2011.11.017","volume":"48","author":"JH Yi","year":"2012","unstructured":"Yi, J. H., Thongprasert, S., Lee, J., Doval, D. C., Park, S. H., Park, J. O. et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur. J. Cancer 48, 196\u2013201 (2012).","journal-title":"Eur. J. Cancer"},{"key":"698_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40880-018-0304-1","volume":"38","author":"JH Kim","year":"2018","unstructured":"Kim, J. H., Lee, S. C., Oh, S. Y., Song, S. Y., Lee, N., Nam, E. M. et al. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. Cancer Commun. (Lond.) 38, 32 (2018).","journal-title":"Cancer Commun. (Lond.)"},{"key":"698_CR25","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.4143\/crt.2017.526","volume":"50","author":"C Yoo","year":"2018","unstructured":"Yoo, C., Han, B., Kim, H. S., Kim K-p, Kim, D., Jeong, J. H. et al. Multicenter phase II study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer. Cancer Res. Treat. 50, 1324\u20131330 (2018).","journal-title":"Cancer Res. Treat."},{"key":"698_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"F Eckel","year":"2007","unstructured":"Eckel, F. & Schmid, R. M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br. J. Cancer 96, 896\u2013902 (2007).","journal-title":"Br. J. Cancer"},{"key":"698_CR27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.dld.2018.11.018","volume":"51","author":"JM Phelip","year":"2019","unstructured":"Phelip, J. M., Edeline, J., Blanc, J. F., Barbier, E., Michel, P., Bourgeois, V. et al. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II\/III study. Dig. Liver Dis. 51, 318\u2013320 (2019).","journal-title":"Dig. Liver Dis."},{"key":"698_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","volume":"4","author":"MA Lowery","year":"2019","unstructured":"Lowery, M. A., Burris, H. A. 3rd, Janku, F., Shroff, R. T., Cleary, J. M., Azad, N. S. et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol. Hepatol. 4, 711\u2013720 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"698_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J. et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J. Clin. Oncol. 36, 276\u2013282 (2018).","journal-title":"J. Clin. Oncol."},{"key":"698_CR30","doi-asserted-by":"crossref","unstructured":"Mazzaferro, V., El-Rayes, B. F., Cotsoglou, C., Harris, W. P., Damjanov, N., Masi, G. et al. ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. J. Clin. Oncol. 35 (Suppl. 15), 4017 (2017).","DOI":"10.1200\/JCO.2017.35.15_suppl.4017"},{"key":"698_CR31","doi-asserted-by":"crossref","unstructured":"Wainberg, Z., Lassen, U., Elez, E., Italiano, A., Curigliano, G., Braud, F. et al. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial. J. Clin. Oncol. 37 (Suppl. 4), 187 (2019).","DOI":"10.1200\/JCO.2019.37.4_suppl.187"},{"key":"698_CR32","doi-asserted-by":"crossref","unstructured":"Belkouz, A., de Vos-Geelen, J., Eskens, F., Mathot, R. A. A., van Gulik, T., van Oijen, M. G. H. et al. Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: a phase II trial. J. Clin. Oncol. 37 (Suppl. 15), 4086 (2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.4086"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0698-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0698-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0698-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:06:35Z","timestamp":1684616795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0698-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3,3]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0698-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"assertion":[{"value":"8 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. The institutional review boards and Medical ethics committee at the Amsterdam UMC, location AMC, reviewed and approved the study protocol (METC_2015-222). All patients provided written informed consent to participate in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Anonymous individual data and the study protocol could be requested from the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}